Introduction
Cardiovascular diseases (CVD) accounted for about half of the 39.5 million deaths caused by non-communicable diseases (NCDs) in 2015 globally and were responsible for nearly 40% of the million deaths attributed to NCDs in sub-Saharan Africa. 1 Hypertension is a major risk factor for death due to cardiovascular, cerebrovascular and renal disorders, and is responsible for about 58% of deaths caused by CVD world-wide. 2 The prevalence of hypertension is projected to rise from 26% in 2010 to 29% by 2025, affecting 1.56 billion people in the developing countries, where HIV/AIDS is also a major public health problem. 3 In Africa, the prevalence of hypertension increased from about 20 to 31% within a decade, 4 and this increase is widely attributed to a demographic transition and the adoption of western lifestyles. A national hypertension survey using a blood pressure threshold of 160/100 mmHg reported a prevalence of 11% in Nigeria, 5 individual studies using a threshold of 140/ 90 mmHg have reported prevalence between 14.5 and 50.5%. 6, 7 Nigeria is the most populous African country with an estimated 170 million population, and with about 3.4 million people living with HIV (PLWH), has the second highest burden of HIV/AIDS in the world. 7 Lifestyle and biological clustering of risk factors for NCDs such as smoking, unfavourable lipid profile and glucose metabolism and endothelial dysfunction are more frequently seen among PLWH than in HIV-negative individuals, [8] [9] [10] and PLWH have a higher prevalence of CVD and other NCDs than non-infected individuals. Although hypertension is only one of the factors that confer risk for CVD, it is a relatively common sign which is easy to diagnose, and it is usually amenable to preventive and therapeutic interventions that reduce morbidity and mortality. 11 Hypertension is often observed among individuals on antiretroviral therapy (ART), and is attributed to increased body weight, male sex and increasing age. [12] [13] [14] However, associations between markers of progression of HIV infection such as viral load, duration of infection and nadir CD4+ count have also been associated with CVD. 15, 16 Whereas there is published literature on the prevalence of hypertension and the risk of CVD among PLWH in sub-Saharan Africa, 17, 18 estimates from large studies are difficult to find in West Africa. In the present study, we determined the prevalence, incidence and correlates of hypertension in treatment naïve PLWH and at 12 months of ART initiation in a large Nigerian cohort.
Methods
This was a mixed study design consisting of a cross sectional survey at baseline and a retrospective component at 12 months of ART involving all newly registered patients attending the AIDS Prevention Initiative of Nigeria (APIN) adult ART clinic of Jos University Teaching Hospital. The APIN clinic is a regional referral centre providing comprehensive HIV/AIDS services for Plateau State, with a population of about 3 million. Following registration at the clinic, all patients are offered lifestyle advice, clinical evaluation and laboratory investigations for the assessment of ART eligibility. Eligibility for ART was according to the 2010 National treatment guidelines 19 ; briefly, a CD4+ ≤350 cells/μl and/or the presence of an AIDS defining illness. Once enrolled, patients are followed 2-weekly, monthly, quarterly and 6-monthly depending on whether they have symptoms or have initiated ART. Sociodemographic, clinical and laboratory information is entered into standardized forms and uploaded onto a single electronic database developed in FileMaker Pro version 10 (Filemaker, Inc., Santa Clara, CA, USA) in dedicated computers to ensure data consistency and completeness. The database is cleaned and curated by trained data management staff. Data errors for this study were further corrected by checking the original patient case notes and the electronic databases.
Data on all patients ≥18 years old who had qualified for ART from 1 January 2011 to 31 December 2013 were retrieved from the database to review their characteristics at the time of initial registration. Patients without baseline blood pressure records and those who had initiated ART at the time of enrolment into the service were excluded from the analysis of baseline hypertension.
Data retrieved included age, sex, body mass index (BMI), total cholesterol (mmol/l), CD4+ cell counts (per μl) and HIV viral load (copies/ml) on enrolment, and ART regimen. The most frequently prescribed first line regimens were: lamivudine+zidovu-dine+nevirapine (59%), and lamivudine or emtricitabine+ tenofovir+efavirenz (41%). The most frequent second line regimens were atazanavir/ritonavir (92%) and lopinavir/ritonavir (8%). Blood pressure (BP) was measured on enrolment and at 12 months with a digital sphygmomanometer (Omron M4-I, Churchill, Oxon, UK, 2005; accuracy ±3%) using appropriate cuffs on the left arm with the patient sitting. Measurements in those with elevated BP were repeated using a manual mercury sphygmomanometer (Accoson, Harlow, Essex, UK) after about 5 minutes of rest and the second measurement was recorded. The same methods were used to assess BP during enrolment and at 12 months of ART. Hypertension was defined as a systolic BP ≥140 mmHg and/or a diastolic blood BP ≥90 mmHg or selfreported pharmacological treatment for hypertension. 20 It is standard practice in our facility for the consulting clinician to interview patients with self-reported use of anti-hypertensives in order to determine the appropriateness of the diagnosis of hypertension. Hypercholesterolemia was defined according to the USA National Cholesterol Education Programme 21 while estimated glomerular filtration rate (eGFR) was derived by the Cockcrof-Gault formula. 22 The main outcome measures were the prevalence of hypertension on enrolment, the cumulative incidence of hypertension within a year of initiating ART and the association of hypertension with traditional and HIV-related risk factors. The precision for the estimates of hypertension based on 2310 patients eligible for the study was ±2% at 95% confidence level, based on an assumed hypertension prevalence of 25%. Okeahialam et al. had reported a prevalence of 21% in a rural community outside Jos in 2012. 23 The identity of all patients was anonymized across the data set by replacing their names with serial numbers.
Statistical analysis was conducted using SPSS 2011(Chicago, IL, USA). Continuous variables were expressed as means±SD, or medians with ranges. Categorical variables were presented as proportions and compared using χ 2 tests. Means were compared using paired or unpaired Student's t tests, as appropriate. Positively skewed data were log 10 transformed. Bivariate analysis was conducted and variables with p<0.25 were entered into multiple logistic regression models. Results of the bivariate analyses and logistic regressions were presented as OR and adjusted OR (AOR), with 95% CI, respectively. A p-value of <0.05 was considered statistically significant.
Results
There were 2753 patients in the database within the study period, out of which 2310 (83.9%) were eligible for analysis of baseline hypertension and 1524 (55.4%) for newly developed hypertension within the first year of ART. The patient selection process is depicted in Figure 1 .
At baseline, 445 (19.3%; 95% CI 17.6-20.9%) of 2310 patients had hypertension of which 248 (55.7%) were unaware they were hypertensive. Only five (2.5%) individuals with hypertension self-reported use of anti-hypertensives. Increasing age, male sex, BMI, CD4+ counts and viral load were associated with hypertension in the bivariate analysis. However, only the first three factors were statistically significant in the multivariate analysis. For every 1 year increase in age, the risk of hypertension increased by 4% (AOR 1.04, 95% CI 1.02-1.06); males were 63% more likely to have hypertension than females (AOR 1.63, 95% CI 1.17-2.28) and 1 kg/m 2 increase in BMI increased the risk of hypertension by 14% (AOR 1.14, 95% CI 1.11-1.18). There were no significant associations with cholesterol and eGFR. The baseline characteristics of the participants are shown in Table 1 .
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Of the 1524 individuals without hypertension at baseline, 473 (31.0%; 95% CI 28.7-33.4%) developed hypertension at one year of commencing ART. In the bivariate analysis, those who developed hypertension were older (p<0.001) and had higher BMI (p<0.001) than those who remained normotensive. There were no significant differences in sex, cholesterol levels, CD4+ counts, viral load, eGFR and ART regimen between those with and without hypertension. For unit increase in continuous variables, only age (AOR 1.04, 95% CI 1.02-1.07, p=0.009) and BMI (AOR 1.10, 95% CI 1.02-1.18, p=0.008) were independently associated with hypertension as shown in Table 2 . When baseline plus newly acquired hypertension were considered together, hypertension was present in 918 (50.3%) of the study cohort.
Missing data analysis
In most cases, less than 10% of data for variables of interest were missing at baseline except for log 10 mean viral load (38%) and eGFR (15.6%). These were analysed and compared as separate categories, with results showing absence of statistically significant difference by age (p=0.436), sex (p=0.112), BMI (p=0.712) and median CD4+ count (p=0.538). Similarly, missing data for log 10 mean viral load (24%) and eGFR (16.5%) were observed with no difference by age (p-value=0.301), sex (p=0.623), BMI (p=0.574) and median CD4+ count (p=0.455) at 12 months.
Discussion
In this large cohort of HIV-positive Nigerians, the prevalence of hypertension was 19.3% at the time of enrolment into the clinic. Hypertension on enrolment was associated with older age, being male and having a higher BMI. There was no association with eGFR, cholesterol level and HIV-related factors. After initiation of ART, a further 473 (31.0%) patients developed hypertension. In this group, hypertension was associated with increasing age and BMI. BMI was the strongest predictor of hypertension at enrolment and after 12 months of ART. The combined prevalence at enrolment and incidence following ART initiation was therefore 50.3%.
The 19% prevalence at enrolment is the same as reported in western Nigeria 24 and the 22% reported in in the US among ART naïve patients. 25 A similar prevalence was also reported from a rural population outside Jos that was not screened for HIV infection, suggesting the prevalence of hypertension in the whole population is likely to be high. 23 However these estimates No BP recordings n=404
Baseline hypertension n=445
No follow up BP n=141
ART <3 months n=200
Baseline Follow up BP n=1524
No hypertension n=1051
Incident hypertension n=473
Baseline BP n=2310 S. E. Isa et al.
are higher than the 2% prevalence in ART-naïve adults in north west Nigeria. 26 Conversely, our prevalence at enrolment is lower than the 26% reported in a Brazilian study. 27 Data on hypertension over extended periods of observation among Nigerian HIV-infected cohorts is scant. A study of 241 patients in the north east reported that 37% had become hypertensive in a two year study. 28 The 31% incidence found at 12 months of ART in the current study is however similar to 28% reported in a study of 5563 patients in Uganda. 18 The incidence in our treated patients is much higher than 17% among ART-experienced patients reported in north west Nigeria, 26 and the 8% in a multi-national data collection on adverse events of anti-HIV drugs (D:A:D Study) involving more than 20 000 patients in industrialized countries, 8 where population prevalence are similar to those in Nigeria 29, 30 Conversely, a prospective study involving 1465 individuals attending integrated HIV/ NCDs clinics in Kibera, Kenya, found hypertension in 87%, even though the community prevalence was 29%. 31, 32 However, the clinics in Kibera also attend to non-infected patients and the study did not state the proportion of HIV-infected individuals who were hypertensive. Most differences in hypertension rates may be explained by variations in study methodologies, sample size and patient characteristics. For example, Friis-Moller et al. 8 defined hypertension as BP ≥150/100 (vs ≥140/90 in this study), and the mean age in the cohort from north east Nigeria 28 was 46 years compared to 37 years in this study.
The associations between hypertension and age, male sex and BMI in HIV-infected patients have been previously reported in Barcelona 33 and Brazil. 27 Although we found these associations, the association with sex disappeared after 12 months of ART. The higher proportion of males (70% vs 40%) and the higher mean BMI (25.7 kg/m 2 vs 22.4 kg/m 2 ) in Barcelona might account for these differences. At enrolment, the mean cholesterol levels were higher in the hypertensive group, though this difference did not quite reach significance (p=0.052), and was in keeping with the study in north eastern Nigeria. 28 Although we did not measure triglycerides, the Brazilian study reported an independent association with triglycerides rather than with total cholesterol. 27 We were unable to measure dietary habits, physical activity, lipid fractions, presence or pattern of lipo-accumulation, smoking and alcohol use. Among the factors measured, there was also no association between hypertension and HIV-related factors, though the CD4+ count and viral load were significant at the univariate analyses (p<0.001) and the CD4+ count was close to significance at multivariate (p=0.062) at the time of enrolment. This is in agreement with a longitudinal study of over 17 000 patients in another DAD study which reported a significant association with viral suppression, but not with CD4+ count.
14 Nonetheless, it is thought that improved well-being brought about by ART, which frequently includes weight gain, CD4+ recovery and viral suppression may be responsible for the development of hypertension. 13 Gazzaruso et al. 34 reported an independent association between hypertension and the metabolic changes induced by ART following exposure to protease inhibitors for 31 months and nucleoside reverse transcriptase inhibitors for 80 months, but that there was no significant association with the ART regimen used. Baekken et al. 35 in contrast reported an independent association between ART and hypertension in a cohort where about 70% of ART was based on protease inhibitor-regimens, with the most effect in patients exposed for >5 years. The lack of association between the ART regimen and hypertension in this study is likely due to only 4% of ART prescription being based on protease inhibitor and that patients had received ART for only one year.
Although our study is a large observational cohort in West Africa and one of the largest in sub-Saharan Africa, it has several limitations. As a retrospective study, some uncertain patient outcomes and missing data, mostly involving eGFR and viral load, might have introduced bias. We had to rely on routine Transactions of the Royal Society of Tropical Medicine and Hygiene blood pressure measurements that were not ideally standardized, and might have over-estimated hypertension due to a 'white coat' effect in which patients in a clinical setting exhibit a blood pressure level above the normal range, which is likely to be most prominent at the time of being diagnosed with a lifelong infection. Nonetheless, this is a reflection of 'real-life' clinical practice and in any case, white coat hypertension is known to predict the development of sustained hypertension. 36 Whilst not commonly available in developing countries, ambulatory blood pressure measurement may have been useful in distinguishing individuals with 'white coat' hypertension from those with sustained hypertension. Also, relevant risk factors of hypertension such as smoking, family history and anthropometric measurements were not routinely collected. This is probably a reflection of the greater emphasis placed on HIV disease alone, but which should now expand to cover the increasingly important NCDs. Lastly, the 12 months exposure to ART was a relatively short period to demonstrate a significant relationship between hypertension and ART regimens.
Conclusions
In conclusion, hypertension is common among HIV/AIDS patients initiated on ART. It is associated with both nonmodifiable factors such as age and modifiable factors such as BMI, which conferred the strongest risk. A 50.3% total prevalence of hypertension may be indicative of a substantial burden in terms of treatment cost and a high risk for the occurrence of vascular events. Consequently, supporting patients to achieve healthy dietary and lifestyle behaviour is paramount for the prevention of NCDs in PLWH. While the relationship between hypertension and ART requires further long term exploration, patients with HIV initiating ART need to be aware of the risk of developing hypertension and HIV treatment programs should integrate services for NCDs such as hypertension.
